repaglinide has been researched along with cyclosporine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brincat, JP; Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Kaatz, GW; Neri, A; Sabatini, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Backman, JT; Kajosaari, LI; Neuvonen, PJ; Niemi, M | 1 |
| Türk, T; Witzke, O | 1 |
| Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T | 1 |
| Li, H; Li, J; Li, Q; Xue, Y | 1 |
2 review(s) available for repaglinide and cyclosporine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for repaglinide and cyclosporine
| Article | Year |
|---|---|
Cyclosporine markedly raises the plasma concentrations of repaglinide.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Glucose; Carbamates; Cross-Over Studies; Cyclosporine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Synergism; Genotype; Humans; Hypoglycemic Agents; Immunosuppressive Agents; In Vitro Techniques; Liver-Specific Organic Anion Transporter 1; Male; Microsomes, Liver; Organic Anion Transporters; Piperidines; Polymorphism, Single Nucleotide | 2005 |
12 other study(ies) available for repaglinide and cyclosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Topics: Animals; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Butyrophenones; Cell Line, Tumor; Cell Membrane Permeability; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Mice; Models, Molecular; Molecular Structure; Piperazines; Piperidines; Protein Binding; Quantitative Structure-Activity Relationship; Quinolones | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
Topics: | 2012 |
Cyclosporine A increases plasma concentrations and effects of repaglinide.
Topics: Carbamates; Cyclosporine; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Organic Anion Transporters; Piperidines | 2006 |
Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant?
Topics: Carbamates; Cyclosporine; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Organic Anion Transporters; Piperidines | 2006 |
Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Topics: Biological Transport; Carbamates; Computer Simulation; Cyclosporine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Piperidines | 2017 |
Repaglinide inhibits cyclosporine A-induced renal tubular toxicity\
by affecting apoptosis and \
Bax\
and \
Bcl-2\
expression
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carbamates; Cyclosporine; Hypoglycemic Agents; Kidney; Kidney Diseases; Kidney Tubules; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley | 2018 |